Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

Mohamed Elmeliegy, Hoi Kei Lon, Diane Wang, Wei An Ma, Lindsay King, Andrea Viqueira, Akos Czibere

Blood (2023) 142 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2023-190341

Published: 2023

Journal Articles

Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption

Ruben Niesvizky, Bertrand Arnulf, Mohamad Mohty, Ajay K. Nooka, Salomon Manier, Michael Tomasson, Nizar J Bahlis, Donald Irby, Jennifer Hibma, Andrea Viqueira, Eric Leip, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2023-182166

Published: 2023

Journal Articles

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Joaquin Martinez-Lopez, Guenther Koehne, Paula Rodriguez Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T Sullivan, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2023-182130

Published: 2023

Journal Articles

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Sheena Sharma, Diane Wang, Hoi-Kei Lon, Pooneh Soltantabar, Andrea Viqueira, Akos Czibere, Anne Hickman, Jane Liang White, Mohamed Elmeliegy

Blood (2022) 140 (Supplement 1): 10036–10038.

https://doi.org/10.1182/blood-2022-169836

Published: 2022

Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Blood (2022) 140 (Supplement 1): 391–393.

https://doi.org/10.1182/blood-2022-162440

Published: 2022

Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere

Blood (2022) 140 (Supplement 1): 7174–7175.

https://doi.org/10.1182/blood-2022-169971

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Michael W. Deininger, Tim H Brummendorf, Jeffrey H. Lipton, Dragana Milojkovic, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3913–3915.

https://doi.org/10.1182/blood-2022-163276

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus

Blood (2021) 138 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2021-150352

Published: 2021

Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Blood (2021) 138 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2021-145709

Published: 2021

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Jorge E. Cortes, MD, Philipp D le Coutre, MD, Carlo Gambacorti-Passerini, MD, Henrik Hjorth-Hansen, MD, Pia Raanani, MD, Valentín Garcia-Gutiérrez, MD PhD, Vamsi Kota, MD, Simon Purcell, Andrea Viqueira, Eric Leip, Tim H Brümmendorf, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134912

Published: 2020

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Bradley Mason, Carla M. Mamolo, PhD, Chloe Johnson, Andrea Viqueira, MD, Adam Gater, Alexander Russell-Smith, Sophi Tatlock, Richa Shah, PharmD, RPh, Joseph C Cappelleri, PhD MPH, MS

Blood (2019) 134 (Supplement_1): 5918.

https://doi.org/10.1182/blood-2019-123444

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Rocco J. Crescenzo, MD, Eric Leip, PhD, Andrea Viqueira, MD, Bart Heeg, PhD

Blood (2018) 132 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2018-99-114827

Published: 2018

Journal Articles

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS MFPM, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3005.

https://doi.org/10.1182/blood-2018-99-110543

Published: 2018

Journal Articles

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Jane F. Apperley, MD, Jenny L. Byrne, FRCP FRCPath PhD, Graeme Smith, Simone Claudiani, Andrea Viqueira, Roxanne Ferdinand, Angela M Carter, Georgina Nock, Dragana Milojkovic

Blood (2016) 128 (22): 5435.

https://doi.org/10.1182/blood.V128.22.5435.5435

Published: 2016

Journal Articles

Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience

Blood (2013) 122 (21): 5117.

https://doi.org/10.1182/blood.V122.21.5117.5117

Published: 2013

NARROW

Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption

Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only